Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

490 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice.
Martens UM, Schröder J, Bengsch F, Sellmann L, Busies S, Frank-Gleich S, Zaiss M, Decker T, Schneeweiss A, Schuler M, Grebhardt S, Zacharias S, Marschner N, Kasenda B, Potthoff K, Vannier C. Martens UM, et al. Among authors: decker t. BMC Cancer. 2023 Jun 13;23(1):543. doi: 10.1186/s12885-023-11046-3. BMC Cancer. 2023. PMID: 37312086 Free PMC article.
Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients.
Muendlein A, Geiger K, Heinzle C, Gaenger S, Winder T, Severgnini L, Reimann P, Brandtner EM, Leiherer A, Drexel H, Decker T, Nonnenbroich C, Dechow T. Muendlein A, et al. Among authors: decker t. J Cancer Res Clin Oncol. 2023 Aug;149(9):6435-6444. doi: 10.1007/s00432-023-04623-3. Epub 2023 Feb 10. J Cancer Res Clin Oncol. 2023. PMID: 36763171
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials.
Hart LL, Im SA, Tolaney SM, Campone M, Pluard T, Sousa B, Freyer G, Decker T, Kalinsky K, Sopher G, Gao M, Hu H, Kuemmel S. Hart LL, et al. Among authors: decker t. Eur J Cancer. 2025 Jan 8;217:115225. doi: 10.1016/j.ejca.2025.115225. Online ahead of print. Eur J Cancer. 2025. PMID: 39826197
Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.
Thill M, Zahn MO, Welt A, Nusch A, Zaiss M, Engelken K, Kaltenecker G, Ringwald K, Gratzke K, Dille S, Kruggel L, Jänicke M, Schulz H, Hagen V, Fricker R, Stickeler E, Harbeck N, Wöckel A, Decker T. Thill M, et al. Among authors: decker t. Int J Cancer. 2024 Dec 20. doi: 10.1002/ijc.35296. Online ahead of print. Int J Cancer. 2024. PMID: 39707595
New Upper Limit on the Axion-Photon Coupling with an Extended CAST Run with a Xe-Based Micromegas Detector.
Altenmüller K, Anastassopoulos V, Arguedas-Cuendis S, Aune S, Baier J, Barth K, Bräuninger H, Cantatore G, Caspers F, Castel JF, Çetin SA, Christensen F, Cogollos C, Dafni T, Davenport M, Decker TA, Desch K, Díez-Ibáñez D, Döbrich B, Ferrer-Ribas E, Fischer H, Funk W, Galán J, García JA, Gardikiotis A, Giomataris I, Golm J, Hailey CH, Hasinoff MD, Hoffmann DHH, Irastorza IG, Jacoby J, Jakobsen AC, Jakovčić K, Kaminski J, Karuza M, Kostoglou S, Krieger C, Lakić B, Laurent JM, Luzón G, Malbrunot C, Margalejo C, Maroudas M, Miceli L, Mirallas H, Navarro P, Obis L, Özbey A, Özbozduman K, Papaevangelou T, Pérez O, Pivovaroff MJ, Rosu M, Ruiz-Chóliz E, Ruz J, Schmidt S, Schumann M, Semertzidis YK, Solanki SK, Stewart L, Vafeiadis T, Vogel JK, Zioutas K; CAST Collaboration. Altenmüller K, et al. Among authors: decker ta. Phys Rev Lett. 2024 Nov 29;133(22):221005. doi: 10.1103/PhysRevLett.133.221005. Phys Rev Lett. 2024. PMID: 39672143
Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer.
Zimmer P, Esser T, Lueftner D, Schuetz F, Baumann FT, Rody A, Schneeweiss A, Hartkopf AD, Decker T, Uleer C, Stoetzer OJ, Foerster F, Schmidt M, Mundhenke C, Steindorf K, Tesch H, Jackisch C, Fischer T, Hanson S, Kreuzeder J, Guderian G, Fasching PA, Bloch W. Zimmer P, et al. Among authors: decker t. BMC Med. 2024 Oct 8;22(1):442. doi: 10.1186/s12916-024-03671-x. BMC Med. 2024. PMID: 39379960 Free PMC article.
Transcriptional control of interferon-stimulated genes.
Babadei O, Strobl B, Müller M, Decker T. Babadei O, et al. Among authors: decker t. J Biol Chem. 2024 Oct;300(10):107771. doi: 10.1016/j.jbc.2024.107771. Epub 2024 Sep 12. J Biol Chem. 2024. PMID: 39276937 Free PMC article. Review.
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.
Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Xu L, Fairhurst RM, Khan S, Denduluri N, Rugo HS, Xu B, Pistilli B; TROPION-Breast01 Investigators. Bardia A, et al. J Clin Oncol. 2025 Jan 20;43(3):285-296. doi: 10.1200/JCO.24.00920. Epub 2024 Sep 12. J Clin Oncol. 2025. PMID: 39265124 Free PMC article. Clinical Trial.
490 results